drugset / Trial / NCT01023230

A Study to Assess DV-601 in Subjects With Chronic Hepatitis B

NCT01023230

Phase 1 Completed 14 enrolled Dynavax Technologies Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if DV-601, an investigational, therapeutic vaccine will be well-tolerated and induce hepatitis B virus (HBV)-specific virological and immunological responses in chronic hepatitis B (CHB) patients.

Timeline

Start
2009-09
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject DV-601 Vaccine
Background Entecavir Small molecule